高压氧作为COVID-19严重低氧血症辅助治疗:一项随机对照试验
这项多中心、开放标签随机对照试验在阿根廷布宜诺斯艾利斯于2020年7月至11月进行,纳入COVID-19严重低氧血症(补氧后SpO2≤90%)患者,随机接受高压氧治疗或呼吸症状标准治疗7天。高压氧计划≥5次(1次/天),90分钟,1.45 ATA。中期分析后试验提前终止,共随机40例(每组20例)。高压氧组纠正低氧血症时间中位3天(IQR 1.0-4.5)vs 对照组中位9天(IQR 5.5-12.5),p<0.010;第3天恢复的OR 23.2(95%CI 1.6-329.6;p=0.001)。对ARDS、机械通气或30天死亡无统计学显著影响。作者认为 findings 支持高压氧治疗COVID-19严重低氧血症的安全性和有效性。
要点
- 纳入COVID-19补氧后SpO2≤90%的严重低氧血症患者,高压氧组纠正低氧血症中位3天(IQR 1.0-4.5)vs 对照组9天(IQR 5.5-12.5),p<0.010。
- 高压氧组第3天低氧血症恢复的OR为23.2(95%CI 1.6-329.6;p=0.001),置信区间宽。
- 高压氧对ARDS、机械通气需求或30天死亡无统计学显著影响。
- 高压氧方案为≥5次(1次/天),每次90分钟,1.45 ATA;实际平均接受6.2±1.2次。
- 试验在50%患者(40例)中期分析后提前终止,原计划样本量80例。
适用人群与场景
- COVID-19且严重低氧血症(补氧后SpO2≤90%)的患者。
- 研究在阿根廷布宜诺斯艾利斯的多中心进行,时间为2020年7月至11月。
诊断标准与关键阈值
- 严重低氧血症定义为补氧后SpO2≤90%。
- 低氧血症纠正定义为氧需求正常化至SpO2≥93%。
处置流程与药物剂量
- 高压氧治疗计划≥5次,1次/天,每次90分钟,1.45 ATA;实际平均接受6.2±1.2次。
- 对照组接受呼吸症状标准治疗7天。
研究设计与关键结果
- 多中心、开放标签随机对照试验,计划样本量80例,中期分析(50%患者)后提前终止,实际随机40例(每组20例),年龄55.2±9.2岁,入院时SpO2 85.1%±4.3%。
- 高压氧组纠正低氧血症时间中位3天(IQR 1.0-4.5)vs 对照组中位9天(IQR 5.5-12.5),p<0.010。
- 高压氧组第3天低氧血症恢复的OR 23.2(95%CI 1.6-329.6;p=0.001)。
- 高压氧对ARDS、机械通气或30天死亡无统计学显著影响。
证据类型、等级与局限
- 证据类型:多中心、开放标签随机对照试验。
- 试验注册号:NCT04477954。
- 局限:试验在中期分析后提前终止,实际样本量40例(计划80例);OR置信区间宽(1.6-329.6)。
对床旁实践的改变
- 作者认为 findings 支持高压氧治疗COVID-19严重低氧血症的安全性和有效性。
- 高压氧可缩短纠正低氧血症时间,但对ARDS、机械通气或30天死亡无统计学显著影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Hyperbaric oxygen (HBO2) therapy has been proposed to treat hypoxaemia and reduce inflammation in COVID-19. Our objective was to analyse safety and efficacy of HBO2 in treatment of hypoxaemia in patients with COVID-19 and evaluate time to hypoxaemia correction.
METHODS: This was a multicentre, open-label randomised controlled trial conducted in Buenos Aires, Argentina, between July and November 2020. Patients with COVID-19 and severe hypoxaemia (SpO2 ≤90% despite oxygen supplementation) were assigned to receive either HBO2 treatment or the standard treatment for respiratory symptoms for 7 days. HBO2 treatment was planned for ≥5 sessions (1 /day) for 90 min at 1.45 atmosphere absolute (ATA). Outcomes were time to normalise oxygen requirement to SpO2 ≥93%, need for mechanical respiratory assistance, development of acute respiratory distress syndrome and mortality within 30 days. A sample size of 80 patients was estimated, with a planned interim analysis after determining outcomes on 50% of patients.
RESULTS: The trial was stopped after the interim analysis. 40 patients were randomised, 20 in each group, age was 55.2±9.2 years. At admission, frequent symptoms were dyspnoea, fever and odynophagia; SpO2 was 85.1%±4.3% for the whole group. Patients in the treatment group received an average of 6.2±1.2 HBO2 sessions. Time to correct hypoxaemia was shorter in treatment group versus control group; median 3 days (IQR 1.0-4.5) versus median 9 days (IQR 5.5-12.5), respectively (p<0.010). OR for recovery from hypoxaemia in the HBO2 group at day 3 compared with the control group was 23.2 (95% CI 1.6 to 329.6; p=0.001) Treatment had no statistically significant effect on acute respiratory distress syndrome, mechanical ventilation or death within 30 days after admission.
CONCLUSION: Our findings support the safety and efficacy of HBO2 in the treatment of COVID-19 and severe hypoxaemia.
TRIAL REGISTRATION NUMBER: NCT04477954.
参考来源
- Cannellotto M, Duarte M, Keller G, et al. Hyperbaric oxygen as an adjuvant treatment for patients with COVID-19 severe hypoxaemia: a randomised controlled trial. Emerg Med J. 2021. PMID: 34907003. doi:10.1136/emermed-2021-211253
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。